Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe, potentially life threatening adverse drug reactions characterized by skin blistering. Previous studies have identified drug-specific and population-specific genetic risk factors with large effects. In this study, we report the first genome-wide association study (GWAS) of SJS/TEN induced by a variety of drugs. Our aim was to identify common genetic risk factors with large effects on SJS/TEN risk. We conducted a genome-wide analysis of 96 retrospective cases and 198 controls with a panel of over one million single-nucleotide polymorphisms (SNPs). We further improved power with about 4000 additional controls from publicly available datasets. No genomewide significant associations with SNPs or copy number variants were observed, although several genomic regions were suggested that may have a role in predisposing to drug-induced SJS/TEN. Our GWAS did not find common, highly penetrant genetic risk factors responsible for SJS/TEN events in the cases selected.
Introduction
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the extreme clinical manifestations of mucocutaneous eruptions. SJS/TEN are the rarest varieties of severe cutaneous adverse reactions, mostly induced by a variety of medications through a dose-independent immune response.
1-2 SJS/TEN are characterized by mortality rates between 1 and 30%, depending on the extent of blistering, and up to 35% of serious sequelae in survivors. 2 Over the past few decades, a series of studies addressed the epidemiology of SJS/TEN in terms of variability according to ethnicity and causative drugs. 3 Each year, SJS/TEN affects eight Asian, 4 and only one to two ethnically European individuals per million persons. Antibacterial sulfonamides (for example, cotrimoxazole), allopurinol and antiepileptic drugs (phenytoin, carbamazepine and lamotrigine) are consistently the most frequent SJS/TEN-inducing drugs. 5 Drug specific relative risk differs significantly among ethnic groups. For instance, carbamazepine accounts for 25-33% of SJS cases in east Asians, but only 5-6% in Europeans. 6 Heritable predisposition to SJS/TEN was recognized by several case-control candidate gene studies, but this is likely to be drug and often ethnicity specific. Indeed, in a broader east Asian population [6] [7] [8] Human leucocyte antigen (HLA)-B*1502 is a predictive marker for carbamazepine-related severe cutaneous adverse reaction with a positive predictive value of 7%. SJS/TEN caused by phenytoin also shows a weaker association with HLA-B*1502. 9 This allele is rare in Europeans, which could be the reason why similar HLA risk factors have not been identified. 10 In contrast, ethnicity does not seem to influence the incidence of allopurinol severe cutaneous adverse reaction, 11 in which HLA-B*5801 has been shown to be strongly associated in both European 12 and Asian populations. 13 Finally, a candidate gene study in Japanese patients with SJS/TEN to a number of drugs showed an association with HLA-A*0260. 14 Although there have been a number of studies investigating the role that candidate genes may have in drug-induced SJS/TEN, no highly reproducible genetic predictors other than HLA-B*1502 and HLA-B*5801 have emerged.
Here, we report the first genome-wide association study (GWAS) of SJS/TEN. In this retrospective study, we used standard phenotypic criteria to identify SJS/TEN cases that were due to a number of drugs. Our aim was to discover highly penetrant and common genetic factors that increase the risk of developing SJS/TEN, which may not necessarily be drug specific.
Materials and methods

Subjects
PGX40001 collection. Cases were defined by Pirmohamed et al. 15 Briefly, cases were retrospectively enrolled and screened by expert review based on SJS/TEN inclusion and exclusion criteria. The controls were collected at the site of case matching for age, gender and ethnicity. Six of the cases were defined as SJS-TEN spectrum, that is, they were within the spectrum of the blistering skin reactions (SJS, overlap syndrome, TEN), but incomplete clinical data meant that we were unable to categorize accurately. In total, 71 cases and 135 controls were genotyped using Illumina 1M in our study (Illumina, http://www.illumina.com).
LAM30004 collection. Cases were defined by Kazeem et al. 16 All cases and controls were epilepsy patients treated with lamotrigine and recruited retrospectively. Cases were patients who developed SJS/TEN or hypersensitivity reactions (although only SJS/TEN cases are included in this study), whereas controls were patients exposed to lamotrigine without developing SJS/TEN. In addition to matching for the drug of interest, the controls were also chosen on the basis of other factors, such as age, ethnicity and concurrent valproic acid usage. SJS/TEN was defined by dermatologists using standard phenotypic criteria. In total, 6 cases and 63 controls were included in this study. November 2007 and March 2008, 19 retrospective Caucasian cases of SJS because of the number of drugs were collected from Dermatology Department at the University of Florence and Dermatology Department at University of Verona. Cases were defined on the basis of three major clinical criteria: pattern of skin lesions, distribution of lesions and percentage of epidermal detachment during the course of the disease. A diagnosis of SJS was considered if blistering did not exceed 10%, whereas TEN cases had 430% of the body surface area blistered, with SJS-TEN overlap cases occupying an intermediate position. 3 Etiology assessment was performed on all cases, and only cases with drug as the most likely cause were included in the study. Exclusion criteria were (a) concomitant human immunodeficiency virus infection, and (b) concomitant immunosuppressant drugs. Ethical approval was provided by the University of Florence Ethics committee.
Italian cases. Between
Control selection
The controls from PGX40001 were collected at the same site as the cases, matched on the basis of ethnicity and gender. The controls in LAM30004 were matched on drug treatment as well as age and ethnicity. No specific control matching was carried out for the Italian cases. We obtained the genotypes of 88 HapMap3 TSI 17 subjects as the controls for the Italian cases. We also included 659 POPRES (population reference sample) controls genotyped by Serious Adverse Events Consortium as the basis for separating sub-populations within Europeans using principal components analysis (PCA; see below). In addition, about 4837 WTCCC2 subjects were analyzed and 4108 of these were chosen to match the northwestern Europeans (nw-EU) cases.
Genotyping
All subjects from PGX40001 and LAM30004 and POPRES controls and Italian collection were genotyped at Expression Analysis (Research Triangle Park, NC, USA). PGX40001 and LAM30004 and were genotype together using Illumina 1M chip, whereas the Italian cases by Illumina 1M-duo chip. The POPRES subjects were genotyped by Illumina 1M or 1M-Duo for another Serious Adverse Events Consortium study 18 The chips contain about 1.07 and 1.2 million markers of single-nucleotide polymorphisms (SNPs) and copy number variant (CNV) probes, respectively. The genotypes of HapMap TSI were downloaded from http://hapmap.org public release no. 27. The genotypes of WTCCC2 subjects were downloaded from The European Genome-phenome Archive (http://www.ebi.ac.uk/ega/)-1958 British Birth Cohort and United Kingdom Blood Service Group (only Illumina 1M data).
Genotype quality control
For each set of genotype data, we applied a series of quality control steps. Specifically, any marker that did not pass any of the following criteria was discarded:
1. Call rate 495%; 2. Minor allele frequency 41%; 3. A P-value for Hardy-Weinberg equilibrium 410 À7 in controls (if applicable).
After applying these criteria, 837 175 SNPs were left in the PGX40001 and LAM30004 subjects. The Italian collection was merged with HapMap TSI subjects. There were 781 191 SNPs left after removing those SNPs that had a significant allele frequency difference between HapMap TSI and Genetic risk factors with large effects on SJS/TEN risk Y Shen et al POPRES Italians. All subjects had o10% of missing genotyping calls.
In addition, we identified subjects that were highly related on the basis of estimated identity-by-descent using PLINK v1.05 19, 20 There were 21 samples with identity-by-descent sharing values 40.2 and o0.9 with at least one other sample. Removing 12 samples resolved the issue (each of removed samples had lower overall SNP call rate than its related sample). There were four pairs of samples with almost identical genotypes (identity-by-descent sharing 40.99). These near-identical samples were further investigated by comparing the genotypes from this study with those from a previous experiment that included Affymetrix 500K (Affymetrix, http://www.affymetrix.com) SNP genotyping. Three samples (two were cases) were found to have significant inconsistency and were excluded. The fourth pair was also identical according to the Affymetrix 500K result and regarded as a true sample duplicate. The sample with the higher SNP call rate was retained. In addition, two cases were removed because of the inconsistency between reported ethnicity and that inferred by PCA (see next section). In total, 18 subjects were discarded, including 5 cases and 13 controls.
When combining data from external sources (such as WTCCC2 and HapMap), we removed SNPs that had significantly different allele frequencies compared with the control set that was genotyped in the same facility as the cases (Fisher's exact test P-value o10 À4 ). We found that all SNPs with potential strand annotation issues were also discarded by this approach.
Principal components analysis
We used the smartPCA program from the EIGENSTRAT package (version 3.0) 21 to conduct PCA in order to expose population structure. SNPs from known regions 22 of longrange linkage disequilibrium were removed before conducting PCA. We first combined the study genotype data with HapMap data to identify major ancestry groups (Europeans, Asians and Africans). We then conducted PCA on Europeans (self-reported non-Hispanic white or European) to separate sub-populations among Europeans.
Statistical analysis
We conducted statistical tests through PLINK v1.05. For the overall European cases and controls, we tested association using logistic regression with gender and the first four eigen scores as covariates under an additive model. For the nw-EU group, we tested associations using Fisher's exact test under an additive model.
Power simulation
The simulation conditions are listed in Supplementary Table  S1 . The procedure was implemented in R (version 2.6-2.9). 23 
CNV analysis
The CNV calls were generated using PennCNV 24 software (April 2009 version). To ensure the accuracy of CNV calling, we applied stringent sample and CNV filtering procedures.
We studied the relationship among the mean and standard deviation of log R ratio (normalized signal intensity from BeadStudio by Illumina) and the number of CNV calls (Supplementary Figure S1) . We included all sample that had a log R ratio standard deviation o0.23, maximum number of total CNV calls o200, maximum number of 100 kb CNV call o20, bioaccumulation factor median40.55 or o0.45, bioaccumulation factor drift 40.002 or waviness factor 40.04 or oÀ0.04. Additionally, to ensure high-confidence CNVs, we excluded individual CNVs if:
1. PennCNV-generated confidence score was o10; 2. Called based on fewer than 10 SNPs/CNV probes; and 3. Spanned within 1 Mb from centromeres or telomeres.
We performed burden and common CNVs association analysis. Any CNV that was present in at least three subjects was considered to be common. 25 Associations were tested using two tails permuted (100 000 times) Fisher's exact analysis using PLINK software, by considering duplications and deletions separately. 16 We also investigated singleton CNVs 4100 kb 26 to find evidence for individual predisposition to SJS/TEN. For this analysis, we adopted a coverage cutoff excluding all CNVs that had coverage 420 genetic markers/CNVs. All analyses were carried out in the nw-EU subjects that passed the genotyped quality control procedure, excluding Italian cases, as they did not have an ethnically matched control group.
Results
Initial GWAS
This study was based on three SJS/TEN collections: PGX40001, 15 LAM30004 16 and an Italian collection (Materials and methods). Both PGX40001 and Italian cases were induced by multiple drugs (Tables 1a and b) , whereas all LAM30004 case were because of lamotrigine. In total, 294 subjects were genotyped, of which 276 (including 91 cases and 185 controls) passed quality control steps (Materials and methods). Genetic structure was investigated by PCA Co-trimoxazole  12  --12  Lamotrigine  9  --9  Amoxicillin  3  2  -5  Phenytoin  7  -1  8  Moxifloxacin  2  -1  3  Carbamazepine  3  --3  Allopurinol  1  2  -3  Clarithromycin  1  2  -3  Others  21  16  -34 Abbreviations: e-EU, eastern Europeans; nw-EU, northwestern Europeans; s-EU, Italians; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis. Six subjects experienced SJS/TEN due to more than one causal drug. (Figure 1b) . For each case, we selected up to seven closest controls based on eigen scores of the first four vectors, resulting in 461 controls that match 72 cases. We tested the association of single SNPs using logistic regression with first four eigen scores and gender as covariates under an additive model ( Figure 2 ). We found no SNPs with a P-value o10 À6 . The top associated SNP was rs6016348 on chromosome 20 (P-value ¼ 1.3 Â 10 À6 ; odds ratio (OR) ¼ 2.9, 95% confidence interval: 1.9-4.6; Table 2 ).
We then tested the association of the SNPs in s-EU group and the nw-EU group separately.
s-EU group. There were 21 cases and 107 controls. Among the controls, 88 were from HapMap TSI, and 18 were from POPRES of Italian origin. To remove the SNPs that may have genotyping errors, we discarded all SNPs with significant different allelic frequencies between the TSI and POPRES controls of Italian origin (Po10 À4 ). We tested associations with 781 191 SNPs that passed quality control and found no SNP with a P-value o10 À6 .
nw-EU group. We first analyzed the nw-EU subjects from PGX40001 and LAM30004 collections only. There were 46 cases and 143 controls, including 59 males and 130 females. We tested associations with 837 070 SNPs that passed quality control. We found no SNPs with P-values o10 À6 .
Improving power by expanding the control set Because of the rarity of SJS/TEN, it is extremely difficult to collect more cases to improve the power of the study in a timely manner. Therefore, we expanded the control set 15 with WTCCC2 publicly available data set, 28 genotyped by Illumina 1M chip. We combined the cleaned WTCCC2 set with the nw-EU group. In the combined set, there were 46 cases and 4251 controls. We applied Fisher's exact test on the data set (Supplementary Figure S2) . The top associated SNP is rs17137412 (chromosome 7, position 7767212, P-value ¼ 1.2 Â 10 À8 , OR: 4.0, 95% confidence interval of OR: 2.5-6.2; minor allele frequency (MAF) in cases versus Genetic risk factors with large effects on SJS/TEN risk controls: 0.33 versus 0.11). This is an intronic SNP within the AC006465.3 hypothetical gene, and close to RPA3. There were no other SNPs with a P-value o10 À6 .
Drug-specific groups
Previous studies with carbamazepine and allopurinol indicate that, it is possible to detect drug-specific risk alleles with large effects based on small numbers of cases. 6, 13, 29 To investigate this, we looked at two drug-specific groups: co-trimoxazole (12 European cases) and lamotrigine (9 European cases).
Co-trimoxazole SJS/TEN cases. No SNPs with a P-value o10
À6
were identified when comparing the 12 cases to 143 nw-EU controls or 2251 WTCCC2 controls.
Lamotrigine SJS/TEN cases. No SNPs with a P-value o10
À6
were identified when comparing the 9 cases with 143 nw-EU controls (including 52 drug-matched controls). Interestingly, the top associated SNP in an additive model (rs12019361, P ¼ 7 Â 10 À6 , OR¼ 12, MAF in all controls: 0.06, MAF in 52 lamotrigine-exposed controls: 0.067) is intronic in the ADAM22, which is a gene involved in epilepsy, 30 a primary indication for this drug.
Association with CNVs
Among the 192 nw-EU individuals who passed the SNP quality control checks, 134 individuals (37 cases and 97 controls) passed stringent quality-control criteria for CNV calling (Materials and methods). A total of 1062 duplications and 2171 deletions were predicted. The numbers and average size of both deletions and duplications were not significantly different between cases and controls. After multi-test correction, none of the common CNVs had a significant association. There was no significant difference in the number of singleton CNVs that are 4100 kb, although the average size of deletions were larger in cases than in controls (458 versus 203 kb, permuted P-value ¼ 0.03). We found 11 unique oversize (4500 kb) CNVs with three of them being 41 Mb (Table 3) .
Power calculations
We conducted post hoc power calculations to better understand the power and the potential benefit from expanding control sets in the context of our study. We assumed a certain OR value under an additive genetic model, and a range of MAFs in the population (MAF Popu ). The MAF in cases (MAF C ) was determined by the OR and MAF Popu . The number of cases and controls were chosen to Table S1 ). All controls were assumed to be population controls. The prevalence of SJS/TEN was set at 0.001, which is likely to be larger than the true value in the European population. The number of latent cases in the population controls was calculated as the product of the prevalence and the total number of controls. The numbers of minor alleles in cases and controls were determined by sampling independently from binomial distributions, with P-value at MAF C and MAF Popu , respectively. For each combination of the condition, we repeated the sampling procedure 10 000 times, and each time calculated the P-values using Fisher's exact test assuming additive models. We then estimated the power as the fraction when the P-value is o5 Â 10 À8 (genome-wide significance).
As expected, the power always increases with the increase in the number of controls. With 46 cases, assuming an OR of 4.0 and MAF Popu of 0.1, which are the conditions that are similar to the top associated SNP in nw-EU SJS/TEN group, the increase in power of detecting genome-wide significant (P-value o5 Â 10 À8 ) markers reaches a plateau of 0.5 at around 2000 controls. The power is 0.18 from the original sample size of 143 controls. Therefore, using publicly available external population controls increases the power by about threefold (Figure 3) . In all, 80 cases are required to achieve a comparable increase in power given the original 143 controls.
Discussion
SJS and TEN are life threatening adverse drug reactions, in which genetic predisposition has been shown to be important with drugs, such as carbamazepine and allopurinol. In this study, we have evaluated patients who we have genotyped previously using a candidate gene approach, 16 and combined them with new patient cohorts exposed to lamotrigine and an Italian group exposed to various drugs. We have then undertaken a GWAS, the first GWAS on SJS/ TEN patients, with the aim to identify common variants that exert large effects on the risk of developing druginduced SJS/TEN. The strengths of the study were as follows: (a) it is the largest set of SJS-TEN patients collected to identify genetic predisposition; (b) all patients were clinically phenotyped consistently using the criteria laid down by Bastuji-Garin et al; 3 (c) only patients, in whom there was plausible drug-related etiology were recruited; and (d) it was undertaken using the most up-to-date genotyping technology. Many different drugs are known to cause SJS/TEN, and this is reflected in the drug groups represented in our study. On the one hand it provides power to identify a common predisposing locus (or loci), but on the other hand it is limited by the fact that the number of patients in each drug group is low. A limitation of this study is that although all cases were deemed as prominently drug caused, they were retrospectively recruited when the etiology assessment process was not standardized comparing with current 
À8
; OR ¼ 4.3, 95% CI: 2.7-6.8).
Genetic risk factors with large effects on SJS/TEN risk Y Shen et al prospective studies, leaving the possibility of including some non-drug-induced cases. We found no SNP with genome-wide significance using the standard definition (P-value o5 Â 10 À8 ) from the overall set of European subjects. From the nw-EU group, we did find a SNP in chromosome 7 with a P-value of about 1 Â 10 À8 and an odds ratio of 4, but it was not replicated in the s-EU group, in which it had an odds ratio o1, even though the MAFs of controls are similar in the nw-EU and s-EU groups. The discrepancy of the effect of this SNP in these two groups may reflect the fact that different drugs are involved (Table 1a) , and the effect of the SNP could be drug-specific (Figure 4) . Therefore, it seems unlikely that there are common and highly penetrant genetic risk factors that are responsible for most of the SJS/TEN events across drugs. Given that many drugs responsible for the SJS/TEN cases, these results do not exclude the possibility that there may be highly penetrant risk alleles with specific drugs in particular ethnic populations.
Our study highlighted a few biologically relevant SNPs (Table 2) , which may contribute to the risk of the event and deserve further investigations. Two SNPs from one of the top associated regions (rs981946 and rs1079284 in chromosome 6) were intronic to gene SLC22A23. This gene encodes a human transporter with structural similarity to the drug transporter SLC22 family. 31 Experimental data suggested that SLC22s are involved in drug transport in kidneys, liver and brain. The interaction of SLC22s with several classes of drugs is well documented, but which of transporters is the main factor for each drug has not been accessed. 32 We investigated the association of SLC22A23 SNPs and b-lactam caused SJS/TEN, as b-lactam antibiotics are substrates for transporters. The result is negative, comparing 16 b-lactam cases and 96 genetically matched controls, the P-value of the SNPs is about 0.08 and OR is about 2.
We found a few singleton CNVs that cover genes with suggestive functions relevant to SJS/TEN. One of them is a 600 kb heterozygous duplication on 12q13, flanked by PREX1 and SULF2 genes. PREX1 encodes for a protein that regulates GTP-mediated responses to inflammatory signals in mouse macrophage. 33, 34 Another interesting CNV is a 2 Mb heterozygous deletion of the telomeric portion of the long arm of chromosome 13 (13q34). The region contains several genes, including LAMP1 (or CD107a). LAMP1 encodes for a lysosome-associated transmembrane glycoprotein, which is a marker of both CD8 þ lymphocytes 35 and skin mast cell activation. 36 The glycoprotein also seems to be implicated in antigen presentation through major histocompatibility complex. 37, 38 We demonstrated that the power of an association study is greatly improved by expanding the set of controls using publicly available genotypes from individuals of the same ethnicity. On the basis of post hoc power calculation, we found that under similar conditions to the top associated SNP from the nw-EU group, the power of detecting genomewide significant SNPs was increased threefold by expanding the control set to 40 times of the number of cases. This is especially important for studies in which the adverse drug reactions is relatively rare, wherein the collection of a large number of cases is difficult, both in terms of time and cost. Furthermore, wherein the adverse drug reaction is rare, the use of drug-exposed controls does not produce an appreciable difference in power over that obtained through the use of population controls. 29 In conclusion, this GWAS highlighted a few interesting genomic regions that may increase the risk of developing SJS/TEN from exposure to a variety of drugs. The absence of SNPs with genome-wide significant association indicates that common risk factors with large effect for most SJS/TEN reactions from different drugs are not likely. To study SJS/ TEN caused by individual drugs, more cases than were available in our study will need to be identified and recruited to achieve reasonable power. This underscores the importance of systematic efforts of collecting drugspecific SJS/TEN cases. It is also consistent with the concept of deep phenotyping, in which patients with apparently similar clinical manifestations may in fact have different pathogenetic biological processes. Stratification on the basis of more precisely defined phenotypes could theoretically increase statistical power. To this end, we will be launching a consortium termed ITCH (International Consortium on Drug Hypersensitivity), whose remit will be to recruit cases of serious cutaneous adverse drug reactions globally. Another future direction is to study rare variants through sequencing. Recent progress on next-generation sequencing technologies [39] [40] [41] has made it feasible to conduct large scale whole-genome or whole-exome resequencing, which has already been demonstrated to be a powerful tool to discover causal genes for Mendelian traits. [42] [43] [44] [45] Thus, applying whole-genome or whole-exome sequencing to the study of rare drug adverse reactions and common diseases is the logical next step.
